简繁EN
Antengene

Company Introduction

3D Medicines, Inc. is a clinical-stage biopharmaceutical company with a mission to help people with cancer live longer and better. Envisioning a future when cancer is managed as a chronic disease, 3D Medicines focuses on the development of differentiated next-generation immuno-oncology drugs, helping cancer patients live with prolonged survival time and a better quality of life. 3D Medicines has established a pipeline with both next-generation biological macromolecule and chemotherapeutic small-molecule drugs, as well as a professional team capable of global development, registration and commercialization operation.

MORE

January 2021

In January, 2021, we signed license agreement with Y-Biologics on the co-development of next-generation T cell bispecific engager.

04
04
04
04
04
04
04
January 2020
March 2020
September 2020
October 2020
November 2020
December 2020
January 2021
In January, 2020, KN035 was awarded orphan drug status by FDA.
In March, 2020, a partnership with Alphamab and Simcere Pharmaceuticals was formed for the development and commercialization of KN035 in China.
In September, 2020, KN035 was granted priority review by CDE.
In October, 2020, we received $140 million investment from Simcere Pharmaceuticals, Efung Capital, China Capital Management and other institutions.
In November, 2020, Envafolimab (KN035), the world's first PD-L1 antibody drug given via subcutaneous Injection submitted new drug application for marketing in China.
In December, 2020, the NDA of Envafolimab (KN035) was officially accepted by the NMPA.
In January, 2021, we signed license agreement with Y-Biologics on the co-development of next-generation T cell bispecific engager.

PipelineThe company has established a multi-core collaborative clinical pipeline

Candidate Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA

Marketing

Candidate
Molecule

Target/Mechanism

Rights

Preclinical

IND

Phase I

Phase Ⅱ

Phase Ⅲ

NDA

Marketing

  • KN035
  • PD-L1
  • Worldwide

  • Pan-cancer (>15 solid tumors including CRC, GC) with MSI-H/dMMR, mono, single-arm, ORR, 2L/3L

  • BTC, combo with chemo vs. chemo, randomized, OS, 1L

  • SC, mono, single-arm, ORR, 2L

  • NSCLC, combo, 1L

  • NSCLC, combo, 2L

  • GC, combo, 1L/2L

  • TMB-H, mono, single-arm, 2L/3L

  • EC, single-arm, combo with lenvatinib, 2L

  • HCC, combo with VEGF inhibitor, 1L/2L

  • RCC, combo with VEGF inhibitor, 1L/2L

MORE

  • 3D189
  • WT1
  • Greater China

  • Multiple indications

  • AML、MPM、OC、UC

MORE

  • 3D229
  • GAS6/AXL
  • Greater China

  • NSCLC/OC/Kidney cancer/Pancreatic cancer

  • OC/Kidney cancer/Bladder cancer

MORE

  • 3D1001+3D1002
  • COX-2 + EP-4
  • Greater China

  • Cancer pain/Chronic pain

MORE

  • 3D185
  • FGFR1/2/3
  • Worldwide

  • BTC/mUC

MORE

  • 3D011
  • PSMA+
    targeted TKI
  • Worldwide

  • HCC/Prostate cancer

MORE

  • 3D197
  • IO therapy for
    multiple
    indications
  • Greater China

  • Multiple indications

MORE

  • 3D057
  • Next generation
    IO therapy
  • Worldwide

  • Multiple indications

MORE

  • 3D059
  • Heptavalent
    version of
    3D189
  • Greater China

  • Multiple indications

MORE

  • 3D060
  • Not disclosed
  • Worldwide

  • Multiple indications

MORE

  • 3D062
  • Not disclosed
  • Worldwide

  • Multiple indications

MORE

Pipeline

  1. KN035
  2. 3D189
  3. 3D229
  4. 3D1001+3D1002
  5. 3D185
  6. 3D011
  7. 3D197
  8. 3D057
  9. 3D059
  10. 3D060
  11. 3D062

CEO QUOTATION

"With the increasing incidence of cancer, cancer has become one of the major public health problems facing mankind; it not only poses a major threat to human health, but also causes a serious burden to economic and social development.

With commitment to the R&D and commercialization of a next-generation of innovative immuno-oncology drugs, 3D Medicines hopes to provide cancer patients across the globe with more effective, more accessible, and more convenient options of next-generation immuno-oncology drugs, thus helping them to live longer and better."


-- John Gong, M.D., Ph.D., Chairman and CEO of 3D Medicines Inc.

MORE

Company News

MORE

Copyright © 3D Medicines Inc. All Rights Reserved